Intrexon Corporation (NYSE:XON) PT Set at $30.00 by Northland Securities
Intrexon Corporation (NYSE:XON) received a $30.00 price objective from stock analysts at Northland Securities in a research report issued on Monday. The firm currently has a “buy” rating on the biotechnology company’s stock. Northland Securities’ target price indicates a potential upside of 38.57% from the stock’s previous close.
Other research analysts also recently issued reports about the stock. Zacks Investment Research upgraded shares of Intrexon Corporation from a “hold” rating to a “buy” rating and set a $24.00 target price for the company in a research report on Tuesday, May 2nd. BidaskClub upgraded shares of Intrexon Corporation from a “sell” rating to a “hold” rating in a research report on Thursday, June 22nd. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average target price of $40.50.
Shares of Intrexon Corporation (NYSE XON) traded up 0.51% during trading on Monday, reaching $21.76. The company had a trading volume of 215,246 shares. The company’s 50 day moving average is $23.55 and its 200-day moving average is $22.08. Intrexon Corporation has a 1-year low of $18.41 and a 1-year high of $32.90. The stock’s market capitalization is $2.60 billion.
Intrexon Corporation (NYSE:XON) last posted its earnings results on Wednesday, May 10th. The biotechnology company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.22) by $0.04. The business had revenue of $53.70 million for the quarter, compared to analyst estimates of $49.08 million. Intrexon Corporation had a negative net margin of 76.32% and a negative return on equity of 21.19%. The company’s revenue for the quarter was up 23.7% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.55) earnings per share. On average, equities research analysts anticipate that Intrexon Corporation will post ($0.91) earnings per share for the current year.
Several hedge funds and other institutional investors have recently modified their holdings of the company. Pacer Advisors Inc. increased its position in Intrexon Corporation by 21.6% in the first quarter. Pacer Advisors Inc. now owns 7,352 shares of the biotechnology company’s stock valued at $146,000 after buying an additional 1,305 shares during the period. SG Americas Securities LLC bought a new position in Intrexon Corporation during the first quarter valued at $164,000. Federated Investors Inc. PA bought a new position in Intrexon Corporation during the second quarter valued at $172,000. Cullinan Associates Inc. bought a new position in Intrexon Corporation during the second quarter valued at $201,000. Finally, John G Ullman & Associates Inc. bought a new position in Intrexon Corporation during the second quarter valued at $212,000. Institutional investors and hedge funds own 84.38% of the company’s stock.
Intrexon Corporation Company Profile
Intrexon Corporation (Intrexon) forms collaborations to create biologically-based products and processes using synthetic biology. The Company’s domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Belgium and Hungary. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components.
Receive News & Ratings for Intrexon Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon Corporation and related companies with MarketBeat.com's FREE daily email newsletter.